β3-Adrenoceptor as a Novel Treatment Strategy for Depressive Disorders
Pharmacy & Pharmacology International Journal · 2014
DOI: 10.15406/ppij.2014.01.00006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy & Pharmacology International Journal, 2014. Verfasst von Zhu Zhou. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Depression is a complex psychiatric disorder which affects more than 17% of population in the United States. There are several generations of anti-depressant drugs. Selective serotonin reuptake inhibitors (SSRIs) are generally considered first line therapy for clinical depression, but this therapeutic modality is limited by a simple kinetic problem: a significant delayed onset of action. Therefore, the search for newer or novel drug targets for depression continues. β3-Adrenoceptors (ARs) together with β1 and β2-ARs, belongs to the G-protein coupled receptor family which has opened new possibilities for exploring the involvement of this receptor in depressive disorders. The present mini review discusses the possibility of β3-ARs application as a novel treatment strategy for the treatment of depression.
Zitieren
APA
Zhou, Z. (2014). β3-Adrenoceptor as a Novel Treatment Strategy for Depressive Disorders. Pharmacy & Pharmacology International Journal. https://doi.org/10.15406/ppij.2014.01.00006
Vancouver
Zhou Z. β3-Adrenoceptor as a Novel Treatment Strategy for Depressive Disorders. Pharmacy & Pharmacology International Journal. 2014. doi:10.15406/ppij.2014.01.00006
BibTeX
@article{Zhou2014,
author = {Zhou, Zhu},
title = {β3-Adrenoceptor as a Novel Treatment Strategy for Depressive Disorders},
journal = {Pharmacy & Pharmacology International Journal},
year = {2014},
doi = {10.15406/ppij.2014.01.00006}
}
EUVIMED